开源证券给予万孚生物买入评级，公司信息更新报告：2025H1业绩承压，国际业务稳中有进

Core Viewpoint - Open Source Securities issued a report on August 21, giving Wanfu Biology (300482.SZ, latest price: 23.14 yuan) a "buy" rating based on several key factors [2] Group 1: Business Performance - The conventional business is under short-term pressure, while drug testing is experiencing growth against the trend [2] - The international market continues to expand, with a constantly enriching product matrix and ongoing localization efforts [2]